FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vaccines (Basel) / Success and Limitation of Equine Influenza Vaccination: The ...
Vaccines2019; 7(4); 174; doi: 10.3390/vaccines7040174

Success and Limitation of Equine Influenza Vaccination: The First Incursion in a Decade of a Florida Clade 1 Equine Influenza Virus that Shakes Protection Despite High Vaccine Coverage.

Abstract: Every year, several epizooties of equine influenza (EI) are reported worldwide. However, no EI case has been identified in France between 2015 and late 2018, despite an effective field surveillance of the pathogen and the disease. Vaccination against equine influenza virus (EIV) remains to this day one of the most effective methods to prevent or limit EI outbreaks and the lack of detection of the pathogen could be linked to vaccination coverage. The aim of this study was to evaluate EI immunity and vaccine coverage in France through a large-scale serological study. A total of 3004 archived surplus serums from French horses of all ages, breeds and sexes were selected from four different geographical regions and categories (i.e., sanitary check prior to exportation, sale, breeding protocol or illness diagnosis). EIV-specific antibody response was measured by single radial hemolysis (SRH) and an EIV-nucleoprotein (NP) ELISA (used as a DIVA test). Overall immunity coverage against EIV infection (i.e., titers induced by vaccination and/or natural infection above the clinical protection threshold) reached 87.6%. The EIV NP ELISA results showed that 83% of SRH positive serum samples from young horses (≤3 years old) did not have NP antibodies, which indicates that the SRH antibody response was likely induced by EI vaccination alone (the HA recombinant canarypoxvirus-based EI vaccine is mostly used in France) and supports the absence of EIV circulation in French horse populations between 2015 and late 2018, as reported by the French equine infectious diseases surveillance network (RESPE). Results from this study confirm a strong EI immunity in a large cohort of French horses, which provides an explanation to the lack of clinical EI in France in recent years and highlights the success of vaccination against this disease. However, such EI protection has been challenged since late 2018 by the incursion in the EU of a Florida Clade 1 sub-lineage EIV (undetected in France since 2009), which is also reported here.
Get Full Text
Publication Date: 2019-11-02 PubMed ID: 31684097PubMed Central: PMC6963532DOI: 10.3390/vaccines7040174Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research paper studies the occurrence and protection against equine influenza (EI) in France by sampling and analyzing serums from French horses. Results indicate a high level of overall immunity but also suggest potential challenges from a Florida Clade 1 sub-lineage EIV.

Objectives and Methodology

  • The researchers aimed to estimate the immunity and vaccine coverage of EI in France by conducting a large-scale serological study. They used archived surplus serums from French horses across various ages, breeds, and contexts.
  • They quantified EIV-specific antibody response by single radial hemolysis (SRH) and EIV-nucleoprotein (NP) ELISA test.

Findings on Immunity and Vaccine Coverage

  • The results exhibited a robust immunity coverage (87.6%) against EIV infection among French horses, indicating an effective vaccination program.
  • SRH test results specified that the antibody response was likely induced by EI vaccination, as 83% of SRH positive serum samples from young horses didn’t have NP antibodies.
  • This supports the absence of EIV circulation in French horse population between 2015 and 2018, reasoning the absence of EI instances during these years.

Evidence of Challenges to EI Protection

  • The research findings also pointed out recent challenges to this EI protection. Since late 2018, there’s been the emergence of the Florida Clade 1 sub-lineage EIV, which wasn’t detected in France since 2009.
  • The arrival of such viruses could potentially pose new and significant obstacles in maintaining the current EI protection level in France.

Implications

  • The study solidifies the success of the EI vaccination program in France, given the high immunity rate witnessed in French horses.
  • However, it also underlines the need for continuous surveillance and adaptation of vaccines to maintain this success, considering the recent emergence of a sub-lineage EIV.

Cite This Article

APA
Fougerolle S, Fortier C, Legrand L, Jourdan M, Marcillaud-Pitel C, Pronost S, Paillot R. (2019). Success and Limitation of Equine Influenza Vaccination: The First Incursion in a Decade of a Florida Clade 1 Equine Influenza Virus that Shakes Protection Despite High Vaccine Coverage. Vaccines (Basel), 7(4), 174. https://doi.org/10.3390/vaccines7040174

Publication

Vaccines
ISSN: 2076-393X
NlmUniqueID: 101629355
Country: Switzerland
Language: English
Volume: 7
Issue: 4
PII: 174

Researcher Affiliations

Fougerolle, Stéphanie
  • Frank Duncombe, LABÉO, 14280 Saint Contest, France. st.fougerolle@gmail.com.
  • NORMANDIE UNIV UNICAEN, Biotargen, 14000 Caen, France. st.fougerolle@gmail.com.
Fortier, Christine
  • Frank Duncombe, LABÉO, 14280 Saint Contest, France. christine.fortier@laboratoire-labeo.fr.
  • NORMANDIE UNIV UNICAEN, Biotargen, 14000 Caen, France. christine.fortier@laboratoire-labeo.fr.
Legrand, Loïc
  • Frank Duncombe, LABÉO, 14280 Saint Contest, France. loic.legrand@laboratoire-labeo.fr.
  • NORMANDIE UNIV UNICAEN, Biotargen, 14000 Caen, France. loic.legrand@laboratoire-labeo.fr.
  • RESPE, 3 rue Nelson Mandela, 14280 Saint-Contest, France. loic.legrand@laboratoire-labeo.fr.
Jourdan, Marion
  • RESPE, 3 rue Nelson Mandela, 14280 Saint-Contest, France. technicien@respe.net.
Marcillaud-Pitel, Christel
  • RESPE, 3 rue Nelson Mandela, 14280 Saint-Contest, France. c.marcillaud-pitel@respe.net.
Pronost, Stéphane
  • Frank Duncombe, LABÉO, 14280 Saint Contest, France. stephane.pronost@laboratoire-labeo.fr.
  • NORMANDIE UNIV UNICAEN, Biotargen, 14000 Caen, France. stephane.pronost@laboratoire-labeo.fr.
  • RESPE, 3 rue Nelson Mandela, 14280 Saint-Contest, France. stephane.pronost@laboratoire-labeo.fr.
Paillot, Romain
  • Frank Duncombe, LABÉO, 14280 Saint Contest, France. romain.paillot@laboratoire-labeo.fr.
  • NORMANDIE UNIV UNICAEN, Biotargen, 14000 Caen, France. romain.paillot@laboratoire-labeo.fr.
  • RESPE, 3 rue Nelson Mandela, 14280 Saint-Contest, France. romain.paillot@laboratoire-labeo.fr.

Grant Funding

  • 2017-008 / IFCE
  • N12-2017 / Fonds Eperon
  • 17E01598/17P04324 / Ru00e9gion Normandie

Conflict of Interest Statement

Authors report no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

This article includes 35 references
  1. Paillot R, El-Hage CM. The Use of a Recombinant Canarypox-Based Equine Influenza Vaccine during the 2007 Australian Outbreak: A Systematic Review and Summary.. Pathogens 2016 Jun 10;5(2).
    doi: 10.3390/pathogens5020042pmc: PMC4931393pubmed: 27294963google scholar: lookup
  2. Heldens JG, Pouwels HG, Derks CG, Van de Zande SM, Hoeijmakers MJ. Duration of immunity induced by an equine influenza and tetanus combination vaccine formulation adjuvanted with ISCOM-Matrix.. Vaccine 2010 Oct 8;28(43):6989-96.
    doi: 10.1016/j.vaccine.2010.08.043pubmed: 20728523google scholar: lookup
  3. Gildea S, Arkins S, Walsh C, Cullinane A. A comparison of antibody responses to commercial equine influenza vaccines following primary vaccination of Thoroughbred weanlings--a randomised blind study.. Vaccine 2011 Nov 15;29(49):9214-23.
    doi: 10.1016/j.vaccine.2011.09.101pubmed: 21983355google scholar: lookup
  4. Gildea S, Arkins S, Walsh C, Cullinane A. A comparison of antibody responses to commercial equine influenza vaccines following annual booster vaccination of National Hunt horses - a randomised blind study.. Vaccine 2011 May 17;29(22):3917-22.
    doi: 10.1016/j.vaccine.2011.03.003pubmed: 21419776google scholar: lookup
  5. Paillot R. A Systematic Review of Recent Advances in Equine Influenza Vaccination.. Vaccines (Basel) 2014 Nov 14;2(4):797-831.
    doi: 10.3390/vaccines2040797pmc: PMC4494246pubmed: 26344892google scholar: lookup
  6. . Announcement: Final 2016-17 Influenza Vaccination Coverage Estimates Available Online.. MMWR Morb Mortal Wkly Rep 2017 Sep 29;66(38):1028.
    doi: 10.15585/mmwr.mm6638a5pmc: PMC5657678pubmed: 28957041google scholar: lookup
  7. Chiu APY, Dushoff J, Yu D, He D. Patterns of influenza vaccination coverage in the United States from 2009 to 2015.. Int J Infect Dis 2017 Dec;65:122-127.
    doi: 10.1016/j.ijid.2017.10.004pubmed: 29042178google scholar: lookup
  8. Marshall E, Salmon D, Bousfiha N, Togola Y, Ouedraogo F, Santantonio M, Dieng CK, Tartière S, Emmanuelli X. Vaccination coverage among social and healthcare workers in ten countries of Samu-social international sites.. Vaccine 2017 Sep 18;35(39):5291-5296.
    doi: 10.1016/j.vaccine.2017.05.014pubmed: 28666760google scholar: lookup
  9. Seo J, Lim J. Trends in influenza vaccination coverage rates in South Korea from 2005 to 2014: Effect of public health policies on vaccination behavior.. Vaccine 2018 Jun 14;36(25):3666-3673.
    doi: 10.1016/j.vaccine.2018.05.024pubmed: 29739721google scholar: lookup
  10. Uchida M, Kaneko M, Hidaka Y, Yamamoto H, Honda T, Takeuchi S, Saito M, Kawa S. High vaccination coverage is associated with low epidemic level of seasonal influenza in elementary schools: an observational study in Matsumoto City, Japan.. BMC Infect Dis 2018 Mar 13;18(1):128.
    doi: 10.1186/s12879-018-3025-9pmc: PMC5851075pubmed: 29534676google scholar: lookup
  11. Ireland JL, Wylie CE, Collins SN, Verheyen KL, Newton JR. Preventive health care and owner-reported disease prevalence of horses and ponies in Great Britain.. Res Vet Sci 2013 Oct;95(2):418-24.
    doi: 10.1016/j.rvsc.2013.05.007pubmed: 23768693google scholar: lookup
  12. Satou K, Nishiura H. Basic reproduction number for equine-2 influenza virus a (h3n8) epidemic in racehorse facilities in japan, 1971. J. Equine Vet. Sci. 2006;26:310–316.
    doi: 10.1016/j.jevs.2006.05.003google scholar: lookup
  13. Fougerolle S, Legrand L, Lecouturier F, Sailleau C, Paillot R, Hans A, Pronost S. Genetic evolution of equine influenza virus strains (H3N8) isolated in France from 1967 to 2015 and the implications of several potential pathogenic factors.. Virology 2017 May;505:210-217.
    doi: 10.1016/j.virol.2017.02.003pubmed: 28292661google scholar: lookup
  14. Gildea S, Fitzpatrick DA, Cullinane A. Epidemiological and virological investigations of equine influenza outbreaks in Ireland (2010-2012).. Influenza Other Respir Viruses 2013 Dec;7 Suppl 4(Suppl 4):61-72.
    doi: 10.1111/irv.12192pmc: PMC5655889pubmed: 24224821google scholar: lookup
  15. Rash A, Morton R, Woodward A, Maes O, McCauley J, Bryant N, Elton D. Evolution and Divergence of H3N8 Equine Influenza Viruses Circulating in the United Kingdom from 2013 to 2015.. Pathogens 2017 Feb 8;6(1).
    doi: 10.3390/pathogens6010006pmc: PMC5371894pubmed: 28208721google scholar: lookup
  16. Favaro PF, Fernandes WR, Reischak D, Brandão PE, Silva SOS, Richtzenhain LJ. Evolution of equine influenza viruses (H3N8) during a Brazilian outbreak, 2015.. Braz J Microbiol 2018 Apr-Jun;49(2):336-346.
    doi: 10.1016/j.bjm.2017.07.003pmc: PMC5913825pubmed: 29100932google scholar: lookup
  17. Singh RK, Dhama K, Karthik K, Khandia R, Munjal A, Khurana SK, Chakraborty S, Malik YS, Virmani N, Singh R, Tripathi BN, Munir M, van der Kolk JH. A Comprehensive Review on Equine Influenza Virus: Etiology, Epidemiology, Pathobiology, Advances in Developing Diagnostics, Vaccines, and Control Strategies.. Front Microbiol 2018;9:1941.
    doi: 10.3389/fmicb.2018.01941pmc: PMC6135912pubmed: 30237788google scholar: lookup
  18. Woodward AL, Rash AS, Blinman D, Bowman S, Chambers TM, Daly JM, Damiani A, Joseph S, Lewis N, McCauley JW, Medcalf L, Mumford J, Newton JR, Tiwari A, Bryant NA, Elton DM. Development of a surveillance scheme for equine influenza in the UK and characterisation of viruses isolated in Europe, Dubai and the USA from 2010-2012.. Vet Microbiol 2014 Mar 14;169(3-4):113-27.
    doi: 10.1016/j.vetmic.2013.11.039pubmed: 24480583google scholar: lookup
  19. Paillot R, Pitel PH, Pronost S, Legrand L, Fougerolle S, Jourdan M, Marcillaud-Pitel C. Florida clade 1 equine influenza virus in France.. Vet Rec 2019 Jan 19;184(3):101.
    doi: 10.1136/vr.l1203pubmed: 30655407google scholar: lookup
  20. Mena J, Brito B, Moreira R, Tadich T, González I, Cruces J, Ortega R, van Bakel H, Rathnasinghe R, Pizarro-Lucero J, Medina R, Neira V. Reemergence of H3N8 Equine Influenza A virus in Chile, 2018.. Transbound Emerg Dis 2018 Dec;65(6):1408-1415.
    doi: 10.1111/tbed.12984pubmed: 30054993google scholar: lookup
  21. Daly J, Daas A, Behr-Gross ME. Collaborative study for the establishment of a candidate equine influenza subtype 2 American-like strain A/EQ/South Africa/4/03 - horse antiserum biological reference preparation.. Pharmeuropa Bio 2007 Dec;2007(1):7-14.
    pubmed: 18413133
  22. Mumford JA, Wood J. Establishing an acceptability threshold for equine influenza vaccines.. Dev Biol Stand 1992;79:137-46.
    pubmed: 1286748
  23. Mumford JA, Jessett D, Dunleavy U, Wood J, Hannant D, Sundquist B, Cook RF. Antigenicity and immunogenicity of experimental equine influenza ISCOM vaccines.. Vaccine 1994 Jul;12(9):857-63.
    doi: 10.1016/0264-410X(94)90297-6pubmed: 7975864google scholar: lookup
  24. Rash A, Woodward A, Bryant N, McCauley J, Elton D. An efficient genome sequencing method for equine influenza [H3N8] virus reveals a new polymorphism in the PA-X protein.. Virol J 2014 Sep 2;11:159.
    doi: 10.1186/1743-422X-11-159pmc: PMC4161859pubmed: 25183201google scholar: lookup
  25. Kumar S, Stecher G, Tamura K. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets.. Mol Biol Evol 2016 Jul;33(7):1870-4.
    doi: 10.1093/molbev/msw054pmc: PMC8210823pubmed: 27004904google scholar: lookup
  26. Gildea S, Arkins S, Cullinane A. Management and environmental factors involved in equine influenza outbreaks in Ireland 2007-2010.. Equine Vet J 2011 Sep;43(5):608-17.
    doi: 10.1111/j.2042-3306.2010.00333.xpubmed: 21496094google scholar: lookup
  27. Fougerolle S, Legrand L, Garrett D, Birand I, Foursin M, D'Ablon X, Bayssat P, Newton RJ, Pronost S, Paillot R. Influential factors inducing suboptimal humoral response to vector-based influenza immunisation in Thoroughbred foals.. Vaccine 2016 Jul 19;34(33):3787-95.
    doi: 10.1016/j.vaccine.2016.05.068pubmed: 27269055google scholar: lookup
  28. Paillot R, Garrett D, Lopez-Alvarez MR, Birand I, Montesso F, Horspool L. The Immunity Gap Challenge: Protection against a Recent Florida Clade 2 Equine Influenza Strain.. Vaccines (Basel) 2018 Jul 2;6(3).
    doi: 10.3390/vaccines6030038pmc: PMC6161116pubmed: 30004410google scholar: lookup
  29. Heldens JG, Pouwels HG, Derks CG, Van de Zande SM, Hoeijmakers MJ. The first safe inactivated equine influenza vaccine formulation adjuvanted with ISCOM-Matrix that closes the immunity gap.. Vaccine 2009 Sep 4;27(40):5530-7.
    doi: 10.1016/j.vaccine.2009.06.085pubmed: 19607950google scholar: lookup
  30. Heldens JG, van Loon AA, van de Zande S. Is there a benefit from an early booster vaccination in the control of equine influenza?. Vet J 2007 Nov;174(3):592-8.
    doi: 10.1016/j.tvjl.2007.03.004pubmed: 17560150google scholar: lookup
  31. Galvin P, Gildea S, Arkins S, Walsh C, Cullinane A. The evaluation of a nucleoprotein ELISA for the detection of equine influenza antibodies and the differentiation of infected from vaccinated horses (DIVA).. Influenza Other Respir Viruses 2013 Dec;7 Suppl 4(Suppl 4):73-80.
    doi: 10.1111/irv.12195pmc: PMC5655885pubmed: 24224822google scholar: lookup
  32. Perglione CO, Gildea S, Rimondi A, Miño S, Vissani A, Carossino M, Cullinane A, Barrandeguy M. Epidemiological and virological findings during multiple outbreaks of equine influenza in South America in 2012.. Influenza Other Respir Viruses 2016 Jan;10(1):37-46.
    doi: 10.1111/irv.12349pmc: PMC4687505pubmed: 26406274google scholar: lookup
  33. OIE Expert Surveillance Panel on Equine Influenza Vaccine Composition. [(accessed on 15 October 2019)];OIE Bull. 2019 2:2–7. Available online: https://oiebulletin.com/index.php?officiel=08-4-1-2019-2-panel-en&edition=7913&pdf=officiel&article=11019.
  34. Garrett D, Montesso F, Fougerolle S, Lopez-Alvarez MR, Birand I, De Bock M, Huang CM, Legrand L, Pronost S, Paillot R. Refinement of the equine influenza model in the natural host: A meta-analysis to determine the benefits of individual nebulisation for experimental infection and vaccine evaluation in the face of decreased strain pathogenicity.. Vet Microbiol 2017 Nov;211:150-159.
    doi: 10.1016/j.vetmic.2017.10.010pubmed: 29102112google scholar: lookup
  35. Paillot R, Rash NL, Garrett D, Prowse-Davis L, Montesso F, Cullinane A, Lemaitre L, Thibault JC, Wittreck S, Dancer A. How to Meet the Last OIE Expert Surveillance Panel Recommendations on Equine Influenza (EI) Vaccine Composition: A Review of the Process Required for the Recombinant Canarypox-Based EI Vaccine.. Pathogens 2016 Nov 25;5(4).
    doi: 10.3390/pathogens5040064pmc: PMC5198164pubmed: 27897990google scholar: lookup

Citations

This article has been cited 14 times.
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.